Literature DB >> 20718185

Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients.

Maria Anastasia Bianchini1, Pier Luca Ceccarelli, Paolo Repetto, Viviana Durante, Diego Biondini, Barbara Bergamini, Alfredo Cacciari.   

Abstract

In this paper, we describe our experience in the treatment of childhood empyema using urokinase. Patients' ages ranged from 2 to 12 years. Urokinase (dosage: 3,100 IU/kg/day) was diluted in normal saline to produce 1000 IU/ml (maximum dosage 100,000 IU in 100 ml of normal saline). After 2 hours, the clamped catheters were released and connected to water-seal suction at a negative pressure of 10 cm H2O. Pleural irrigations were continued once a day until thoracostomy tube output decreased to less than 10 ml/day (urokinase treatment mean duration: 11.5 days). The complete resolution of the chest effusion was assessed on chest ultrasound scan and radiographs. None of the patients experienced any side effects due to urokinase. It would now seem reasonable to advocate small chest tube thoracostomy and intrapleural urokinase as first-line treatment of pleural empyema in children, with surgery indicated as a secondary intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718185

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  4 in total

1.  Quality improvement guidelines for pediatric abscess and fluid drainage.

Authors:  Mark J Hogan; Francis E Marshalleck; Manrita K Sidhu; Bairbre L Connolly; Richard B Towbin; Wael A Saad; Ann Marie Cahill; John Crowley; Manraj K S Heran; Eric J Hohenwalter; Derek J Roebuck; Michael J Temple; T Gregory Walker; John F Cardella
Journal:  Pediatr Radiol       Date:  2012-11-02

2.  The time course of resolution of adhesions during fibrinolytic therapy in tetracycline-induced pleural injury in rabbits.

Authors:  Andrey A Komissarov; Galina Florova; Ali O Azghani; Ann Buchanan; William M Bradley; Chris Schaefer; Kathleen Koenig; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-07-10       Impact factor: 5.464

3.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

Review 4.  From Bedside to the Bench-A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema.

Authors:  Sophia Karandashova; Galina Florova; Steven Idell; Andrey A Komissarov
Journal:  Front Pharmacol       Date:  2022-01-20       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.